The status of platinum anticancer drugs in the clinic and in clinical trials.

@article{Wheate2010TheSO,
  title={The status of platinum anticancer drugs in the clinic and in clinical trials.},
  author={Nial J. Wheate and Shonagh Walker and Gemma E Craig and Rabbab Oun},
  journal={Dalton transactions},
  year={2010},
  volume={39 35},
  pages={
          8113-27
        }
}
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered clinical trials with only two (carboplatin and oxaliplatin) of these gaining international… 

Figures and Tables from this paper

Platinum-based drugs: past, present and future

TLDR
The main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biologically active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems are reviewed.

Platinum-Based Antitumor Drugs and Their Liposomal Formulations in Clinical Trials

TLDR
This review focuses on liposomal drugs, which are currently at different stages of clinical trials for platinum-based antitumor drugs, including the published data on the composition, how they act, and the results of preclinical and clinical trials.

The state-of-play and future of platinum drugs.

TLDR
Functional genomics is now playing an increasing role in predicting patients' responses to platin chemotherapy and their likelihood of experiencing severe side effects, reflecting a shift in research focus from new drug design to improved formulations of already approved platin drugs.

Comparative assessment of clinical trials, indications, pharmacokinetic parameters and side effects of approved platinum drugs

TLDR
The observational study on pharmacokinetic parameters shows that protein binding decreases in order, and the summarizing of the hystoric data for the stages of the developlement of these drugs includes the comparison of pharmacokimetic parameters, side effecs and the dose-liniting factors of the drugs.

Platinum compounds: a hope for future cancer chemotherapy.

TLDR
The present article describes the current status of cis-platin and its analogues in cancer chemotherapy and attempts have been made to describe the future perspectives of these drugs in the cancer treatment.

Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases

TLDR
The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cisplatin, Carboplatin, Oxali Platin, Nedaplatin), Lobaplatin; and Satraplatin to overcome drug resistance and reduction of toxicity.

Nanoparticles: the future for platinum drugs or a research red herring?

TLDR
The focus of this editorial is on the nanoparticle-based delivery of platinum drugs, and whilst this seems the logical next step in platinum development, their commercialization may not be as straight forward as it would be for small molecule platinum drugs and potentially more risky.

A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

TLDR
It is the combination of toxicity with modest efficacy that led to discontinuation of navitoclax, a selective, potent, orally bioavailable, small molecule Bcl-2 inhibitor in patients with solid tumors.

Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer

TLDR
This blocked platinum complex is not able to reverse cisplatin resistance to a significant extent in vivo and its mechanisms and kinetics and of DNA damage failed to produce significant clinical results compared to second-line standard therapy for lung cancer.
...

References

SHOWING 1-10 OF 196 REFERENCES

Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.

TLDR
If the encouraging in vitro activity shown by new compounds, such as ZD0473 and BBR3464 translates into efficacy in the clinic, they may offer an extended spectrum of activity which includes patients with ovarian cancer resistant to the classical platinum drugs.

Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue

TLDR
Using satraplatin as an alternative platinum cytotoxic agent is particularly attractive because of the convenience of administration, milder toxicity profile, lack of cross-resistance with cisplatin, theoretical advantage as a radiosensitizer, and activity in cancers historically nonresponsive to platinum drugs.

Cisplatin and platinum drugs at the molecular level. (Review).

TLDR
This review summarizes the molecular mechanisms of platinum compounds for DNA damage, DNA repair and induction of apoptosis via activation or modulation of signaling pathways and explores the basis of platinum resistance.

Phase II trial of zeniplatin (CL 286 558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy

TLDR
Although the drug was well tolerated, with moderate emesis and bone marrow suppression being observed in most patients, further development of this drug has been discontinued because of the severe renal toxicity observed in other clinical trials of this cytotoxic agent.

The resurgence of platinum-based cancer chemotherapy

TLDR
Key developments include the elucidation of mechanisms of tumour resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clinical combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.

A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.

TLDR
Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines and has no activity in platinum-resistant epithelial ovarian cancer.

Organo-platinum complexes as antitumor agents (review).

TLDR
The current clinical literature indicates clearly that the full potential of this drug has not yet been realized, and hydration and diuresis have served to mitigate much of the nephrotoxicity, while significant strides toward amelioration of the nausea and vomiting have also been achieved.

Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer

TLDR
Both iproplatin and carboplatin have limited activity in previously treated women with advanced breast cancer when given in conventional dosages, and at the given dose schedulescarboplatin was more myelosuppressive than ipro Platin.

Results of phase II clinical trial of cycloplatam in refractory solid tumors

TLDR
Cycloplatam, a new platinum derivative, evolved at N.S. Kurnakov Institute of General and Inorganic Chemistry in 1982, has been added to the arsenal of Russian cytostatic drugs, having passed phase I trials, and may be recommended both for oral and intracavitary administration.
...